Table 1.
Characteristics and Outcomes of 24 Vaccine-Breakthrough Infectionsa
| Valuesb | |
|---|---|
| Demographic characteristics | |
| Age, mean (SD), range, years | 37.8 (13.4), 20.9–77.7 |
| Male, n (%) | 17 (71) |
| Race/ethnicity, n (%) | |
| Asian | 2 (8) |
| Black | 1 (4) |
| Hispanic | 3 (13) |
| Native Hawaiian | 1 (4) |
| White | 17 (71) |
| Occupational characteristics and military status, n (%) | |
| Active duty | 19 (79) |
| Dependent | 4 (17) |
| Retired | 1 (4) |
| Healthcare worker | 15 (63) |
| Risk behaviors, n (%) | |
| Lives with another adult | 15 (71) |
| Lives with children | 7 (50) |
| Close contact with person with COVID-19 in past monthc | 13 (57) |
| Stayed 6 feet away from people in public more than half the time in past month | 19 (83) |
| Increased frequency of handwashing in the past month | 15 (65) |
| Wore mask all the time in the past month | 19 (83) |
| Comorbidities, n (%) | |
| Any comorbidity | 8 (33) |
| Multiple comorbidities | 3 (13) |
| Hypertension | 4 (17) |
| Asthma or chronic obstructive pulmonary disease | 3 (13) |
| Obesity | 2 (8) |
| Diabetes | 2 (8) |
| Chronic kidney disease | 2 (8) |
| Renal transplant | 1 (4) |
| History of venous thromboembolism | 1 (5) |
| Immunosuppressant medication, n (%) | 1 (4) |
| None | 16 (67) |
| Vaccine product received, n (%) | |
| BNT162b2 (Pfizer-BioNTech) | 22 (92) |
| mRNA-1273 (Moderna) | 2 (8) |
| Illness onset from time of final dose,d median (IQR, range), days | 50.5 (31.5–73.5, 15–95) |
| Symptom severity, n (%) | |
| Never had symptoms | 5 (24) |
| Mild | 7 (33) |
| Moderate | 6 (29) |
| Severe | 3 (14) |
| Critical | 0 (0) |
| Illness outcomes and other characteristics, n (%) | |
| Prior SARS-CoV-2 infection | 0 (0) |
| Hospitalized | 0 (0) |
| Feeling back to normale | 6 (35) |
| Days to recovery,f median (range) | 5 (0–14) |
“None” refers to no comorbidities.
Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
aRestricted to those with illness onset ≥14 days after final dose of vaccination.
bDenominator varies based on response rate.
cBased on the question: “In the month before you were ill, tested for, or exposed to COVID-19, did you have close contact (eg, caring for or living with) a person who tested positive for COVID-19 or had symptoms of COVID-19 such as fever and/or acute respiratory illness?”
dDerived from time to earliest SARS-CoV-2 test positivity in those without symptoms.
eAt time of interview.
fIn those recovered by time of interview (n = 6).